Comparison of the expression of cluster of differentiation (CD)39 and CD73 between propofol- and sevoflurane-based anaesthesia during open heart surgery

Chung-Sik Oh, Karam Kim, Woon-Seok Kang, Nam-Sik Woo, Po-Soon Kang, Jun-Seok Kim, Hang-Rae Kim, Seung-Hyun Lee & Seong-Hyop Kim

High expression of cluster of differentiation (CD)39 and CD73 has cardio-protective effects. We hypothesised that the expression of CD39 and CD73 would differ between propofol- and volatile anaesthetic-based anaesthesia in patients undergoing open heart surgery (OHS). The objective of this prospective randomized trial was to compare the changes in CD39 and CD73 levels in CD4+ T cells between propofol- and sevoflurane-based anaesthesia during OHS. The study randomly allocated 156 patients undergoing OHS to a propofol or sevoflurane group. Blood was obtained preoperatively and up to 48 hours after weaning from cardiopulmonary bypass (CPB). The expression levels of CD39 and CD73 in circulating CD4+ T cells, serum cytokines and other laboratory parameters were analysed. The primary outcome was the expression of CD39 and CD73 on CD4+ T cells. Demographic data and perioperative haemodynamic changes did not show significant differences between the two groups. The expression of CD39 and CD73 in the sevoflurane group was significantly lower than in the propofol group (P < 0.001). Other laboratory findings including cardiac enzymes and cytokine levels, did not show significant intergroup differences. Propofol attenuated the decrease in CD39 and CD73 in circulating CD4+ T cells compared to sevoflurane-based anaesthesia during OHS.

Open heart surgery (OHS) with aortic cross clamping induces ischemia-reperfusion injury (IRI) accompanied by a systemic inflammatory response, resulting in critical postoperative complications. Propofol and volatile anaesthetics are the most popular agents for OHS, and propofol may be a useful organ-protective anaesthetic due to its anti-inflammatory properties. In addition, volatile anaesthetics may have organ-protective properties through their preconditioning effect. The choice of anaesthetic for OHS is important to minimise inflammatory responses and related postoperative complications. However, the most favourable anaesthetics during OHS have not been identified.

Cluster of differentiation (CD)39 and CD73 contribute to adenosine formation, where adenosine shifts the pro-inflammatory role of adenosine triphosphate (ATP) towards an anti-inflammatory role. The cardiac protective roles of CD39 and CD73 against IRI have been demonstrated in previous studies. However, a comparison of the change in CD39 and CD73 expression between propofol- and volatile anaesthetic-based anaesthesia during OHS has not been conducted. Therefore, characterising the responses of CD39 and CD73 in patients...
anaesthetised by propofol or volatile anaesthetics during OHS could increase our understanding on the mechanism underlying the anti-inflammatory effect of propofol and volatile anaesthetics against IRI during OHS.

We hypothesised that the expression of CD39 and CD73 would differ between propofol- and volatile anaesthetic-based anaesthesia in patients undergoing OHS. This study was designed to investigate the expression CD39 and CD73 in the circulating CD4+ T cells of patients undergoing OHS under propofol- and sevoflurane-based anaesthesia.

Results

In total, 173 patients from May 2014 to December 2016 were eligible for the study. A total of 17 patients were excluded for the following reasons: 7 refused to participate, 3 had a preoperative infection, and 7 had a previous history of cancer, and there were no adverse events during the study. Therefore, 156 patients were included in the final analysis (78 in the propofol group and 78 in the sevoflurane group) (Fig. 1). The patient demographics were similar between the propofol and sevoflurane groups (Table 1). Perioperative haemodynamic changes up to 48 hours after weaning from CPB were also similar between the two groups (Table 2).

Expression of CD39 and CD73 in circulating helper T cells during OHS.

The expression of CD39 in circulating CD4+ T cells was lowest 3 hours after weaning from CPB and increased with time (Supplementary Fig. 1). The expression of CD73 in circulating CD4+ T cells was lowest immediately after weaning from CPB and increased with time (Supplementary Fig. 2).

Expression of CD39 and CD73 in circulating helper T cells between propofol- and sevoflurane-based anaesthesia during OHS.

The overall change in CD39 expression in circulating CD4+ T cells was significantly lower in the sevoflurane group than in the propofol group (P < 0.001) (Fig. 2). Especially, the expression of CD39 in circulating CD4+ T cells was significantly lower from 3 hours until 48 hours after weaning from CPB in the sevoflurane group with Bonferroni's correction (Fig. 2). The overall change in CD73 expression in circulating CD4+ T cells was also significantly lower in the sevoflurane group than in the propofol group (P < 0.001) (Fig. 3). Especially, the expression of CD73 in circulating CD4+ T cells from immediately after up to 48 hours after weaning from CPB was significantly lower in the sevoflurane group with Bonferroni's correction (Fig. 3).

Expression of CD39 and CD73 in circulating regulatory T cells during OHS.

The pattern of CD39 and CD73 expression in circulating CD4+CD25 Foxp3+ T cells was similar to the pattern in CD4+ T cells. The expression of CD39 in circulating CD4+CD25 Foxp3+ T cells was lowest 3 hours after weaning from CPB and increased with time (Supplementary Fig. 3). The expression of CD73 in circulating CD4+CD25 Foxp3+ T cells was lowest immediately after weaning from CPB and increased with time (Supplementary Fig. 4).

Expression of CD39 and CD73 in circulating regulatory T cells in propofol- and sevoflurane-based anaesthesia during OHS.

The expression of CD39 in circulating CD4+CD25 Foxp3+ T cells was lower in the sevoflurane group than in the propofol group. The expression of CD73 in circulating CD4+CD25 Foxp3+ T cells was also lower in the sevoflurane group. However, the overall change in CD39 and CD73 expression in circulating CD4+CD25 Foxp3+ T cells did not differ significantly between the groups (P = 0.161 for CD39 and P = 0.068 for CD73) (Supplementary Figs 5 and 6).

Mean fluorescence intensity of CD39 and CD73 in circulating helper T cells and regulatory T cells.

The patterns of the mean fluorescence intensity of CD39 and CD73 in circulating helper T cells and regulatory T cells were similar to the results regarding frequency (Supplementary Table 1).

Changes in laboratory results and cytokines with propofol- versus sevoflurane-based anaesthesia.

The laboratory results did not differ between the two groups (Table 3). No pro- or anti-inflammatory
|                              | Propofol group (n = 78) | Sevoflurane group (n = 78) | P      |
|------------------------------|-------------------------|---------------------------|--------|
| Sex                          | 40 (51.3)               | 30 (38.5)                 | 0.147  |
| Age (years)                  | 54.0 (45.0–64.0)        | 58.7 (41.0–71.0)          | 0.428  |
| Height (cm)                  | 162.8 ± 10.0            | 162.5 ± 6.8               | 0.825  |
| Weight (kg)                  | 62.5 (54.8–68.9)        | 57.0 (55.7–70.0)          | 0.644  |
| Underlying disease           |                         |                           |        |
| Hypertension                 | 28 (35.9%)              | 34 (43.6%)                | 0.413  |
| Diabetes mellitus            | 7 (9.0%)                | 5 (6.4%)                  | 0.764  |
| Arrhythmia                   | 17 (21.8%)              | 10 (12.8%)                | 0.204  |
| CVA                          | 5 (6.4%)                | 3 (3.8%)                  | 0.717  |
| Type of operation            |                         |                           | 0.231  |
| AVP                          | 37 (47.4%)              | 36 (46.2%)                |        |
| AVR                          | 3 (3.8%)                | 9 (11.5%)                 |        |
| MVP                          | 20 (25.6%)              | 16 (20.5%)                |        |
| PVR                          | 4 (5.1%)                | 6 (7.7%)                  |        |
| TAP                          | 3 (3.8%)                | 0 (0.0%)                  |        |
| DVP                          | 11 (14.1%)              | 11 (14.1%)                |        |
| Preoperative LV ejection fraction (%) | 65.0 (60.9–68.0) | 63.4 (59.0–71.6)          | 0.584  |
| Anaesthetics                 |                         |                           |        |
| Propofol (mg)                | 994.0 (985.0–1024.0)    | 0.0 (0.0–0.0)             | 0.000  |
| Remifentanil (μg)            | 6289.0 (4819.0–8164.0)  | 6256.5 (4315.0–8264.0)    | 0.398  |
| Fluid requirements           |                         |                           |        |
| Crystalloid (ml)             | 1400.0 (1300.0–1800.0)  | 1400.0 (1300.0–1900.0)    | 0.741  |
| Colloid (ml)                 | 600.0 (500.0–700.0)     | 600.0 (500.0–600.0)       | 0.138  |
| Duration of anaesthesia (min) | 410.0 (350.0–475.0)     | 401.5 (360.0–456.0)       | 0.348  |
| Duration of operation (min)  | 335.0 (285.0–400.0)     | 335.0 (290.0–365.0)       | 0.932  |
| Duration of cardiopulmonary bypass (min) | 164.5 (132.0–198.0) | 168.0 (145.0–227.0)       | 0.407  |
| Duration of aortic cross clamp (min) | 108.0 (79.0–137.0) | 109.0 (102.0–149.0)       | 0.256  |
| Duration of mechanical ventilation (min) | 1643.0 (1400.0–1894.0) | 1605.0 (1505.0–2098.0)    | 0.424  |
| Duration of ICU stay (min)   | 4090.5 (2810.0–4325.0)  | 4065.0 (2780.0–5106.0)    | 0.932  |
| Duration of hospital stay (days) | 19.0 (16.0–22.0)   | 20.0 (17.0–22.0)          | 0.362  |
| Previous medications         |                         |                           |        |
| ARB                          | 23 (29.5%)              | 28 (35.9%)                | 0.495  |
| CCBR                         | 13 (16.7%)              | 8 (10.3%)                 | 0.348  |
| Beta blocker                 | 3 (3.8%)                | 5 (6.4%)                  | 0.717  |
| Nitrates                     | 9 (11.5%)               | 11 (14.1%)                | 0.811  |
| Aspirin                      | 19 (24.4%)              | 17 (21.8%)                | 0.849  |
| Statin                       | 5 (6.4%)                | 5 (6.4%)                  | 1.000  |
| Type of valvular disease     |                         |                           | 0.648  |
| AR                           | 18 (23.1%)              | 19 (24.4%)                |        |
| AS                           | 22 (28.2%)              | 26 (33.3%)                |        |
| MR                           | 16 (20.5%)              | 13 (16.7%)                |        |
| MS                           | 4 (5.1%)                | 3 (3.8%)                  |        |
| PR                           | 4 (5.1%)                | 6 (7.7%)                  |        |
| TR                           | 3 (3.8%)                | 0 (0.0%)                  |        |
| DVD                          | 11 (14.1%)              | 11 (14.1%)                |        |
| Perioperative drugs          |                         |                           |        |
| Dopamine (mg)                | 41.6 (17.6–63.9)        | 31.7 (15.2–45.9)          | 0.142  |
| Dobutamine (mg)              | 0.0 (0.0–11.2)          | 0.0 (0.0–12.1)            | 0.526  |
| Milrinone (mg)               | 0.0 (0.0–0.9)           | 0.0 (0.0–0.6)             | 0.259  |
| Phenylephrine (mg)           | 0.6 (0.0–1.5)           | 0.5 (0.0–1.2)             | 0.370  |
| Norepinephrine (mg)          | 0.0 (0.0–0.0)           | 0.0 (0.0–0.0)             | 0.652  |
| Isoproterenol (mg)           | 0.0 (0.0–0.0)           | 0.0 (0.0–0.0)             | 0.388  |
| Nitroglycerine (mg)          | 0.0 (0.0–0.0)           | 0.0 (0.0–0.0)             | 0.796  |
| Transfusion requirements     |                         |                           |        |
| pRBC (units)                 | 4.0 (2.0–6.0)           | 5.0 (3.0–6.0)             | 0.095  |
| FFP (units)                  | 1.5 (0.0–2.0)           | 1.0 (0.0–2.0)             | 0.557  |
| Continued                    |                         |                           |        |
cytokines, such as interleukin (IL)−1, IL-6, IL-10, IL-17, interferon (IFN)−γ, and tumour necrosis factor (TNF)−α, showed significant intergroup differences (Table 4).

**Discussion**

This study showed that the expression of CD39 and CD73 in circulating helper T cells was low immediately after weaning from CPB and recovered over time. In addition, the CD39 and CD73 levels in circulating helper T cells were higher with propofol-based anaesthesia than sevoflurane-based anaesthesia during OHS.
Previous studies showed that CD39 and CD73 have organ-protective effects against IRI\(^9,13–16\). Kim et al. showed that CD73 prevents renal IRI\(^15\) and Bonner et al. showed that up-regulation of CD39 and CD73 confers myocardial protection against cardiac IRI\(^16\). In addition, blocking CD39 and CD73 could induce organ injury by inhibiting adenosine formation after IRI\(^17,18\). Meanwhile, OHS involves aortic cross clamping for several hours. Organ blood supply depends on CPB during this 'myocardial ischemic' period. After the main surgical procedure, the aortic cross clamp is released and weaning from CPB should follow. Intense IRI related inflammation occurs during this time before and after weaning from CPB\(^2\). The low expression levels of CD39 and CD73 immediately and 3 hours after weaning from CPB in this study support the notion that this period had the greatest IRI related inflammation during OHS.

Several studies have shown the beneficial effects of volatile anaesthetics relative to propofol during cardiac surgery\(^19,20\), indexed by lower creatine kinase-MB (CK-MB) levels with volatile anaesthetics compared to propofol-based anaesthesia. However, cardiac enzymes do not guarantee immune status during OHS since they are associated only with myocardial injury related to surgical trauma\(^21\). In addition, some reports found no differences in cardiac enzyme levels between propofol- and sevoflurane-based anaesthesia during cardiac surgery\(^22\). Similarly, we found no significant difference in cardiac enzyme and cytokine levels between the two groups. Various perioperative factors, such as the intensity of surgical trauma, haemodynamic changes, transfusion, and drugs, can affect cardiac enzyme and cytokine levels\(^23–25\) and could be confounding factors. However, our results...
|          | Propofol group (n = 78) | Sevoflurane group (n = 78) | P   |
|----------|-------------------------|-----------------------------|-----|
| WBC (/μl) |                         |                             |     |
| Preop    | 6395 (5480–7260)        | 6523 (5710–7670)            | 0.144 |
| 3 hours  | 8995 (6280–10950)       | 9715 (7020–11532)           | 0.405 |
| 24 hours | 11240 (9550–13500)      | 11250 (9365–12545)          | 0.850 |
| 48 hours | 11740 (10000–14000)     | 11730 (9845–13025)          | 0.897 |
| Neutrophils (%) |                    |                             |     |
| Preop    | 52.8 ± 10.2             | 52.0 ± 9.4                  | 0.639 |
| 3 hours  | 86.4 (81.9–88.7)        | 85.9 (84.2–88.4)            | 0.674 |
| 24 hours | 88.3 (84.3–90.5)        | 86.0 (83.4–90.3)            | 0.216 |
| 48 hours | 89.0 (85.3–91.4)        | 87.0 (84.2–91.1)            | 0.306 |
| Lymphocytes (%) |                  |                             |     |
| Preop    | 34.6 (28.9–41.3)        | 34.1 (31.1–40.5)            | 0.844 |
| 3 hours  | 8.9 (5.6–12.0)          | 7.7 (5.8–10.9)              | 0.516 |
| 24 hours | 4.3 (3.3–5.5)           | 4.3 (3.7–4.7)               | 0.585 |
| 48 hours | 6.5 (5.7–7.9)           | 6.4 (5.9–7.1)               | 0.633 |
| ESR (mm/hour) |                        |                             |     |
| Preop    | 10.0 (3.0–16.0)         | 9.0 (7.0–18.0)              | 0.128 |
| 3 hours  | 2.0 (2.0–2.0)           | 2.0 (2.0–2.0)               | 0.220 |
| 24 hours | 2.0 (2.0–5.0)           | 2.5 (2.0–4.0)               | 0.610 |
| 48 hours | 2.0 (1.0–4.0)           | 2.0 (1.0–3.0)               | 0.821 |
| hs-CRP (mg/dl) |                    |                             |     |
| Preop    | 0.3 (0.2–0.4)           | 0.3 (0.3–0.3)               | 0.386 |
| 3 hours  | 0.2 (0.1–0.3)           | 0.2 (0.1–0.3)               | 0.101 |
| 24 hours | 4.5 (3.2–6.0)           | 4.4 (3.1–6.1)               | 0.852 |
| 48 hours | 5.0 (3.7–6.5)           | 4.7 (3.4–6.4)               | 0.565 |
| CK-MB (ng/ml) |                        |                             |     |
| Preop    | 1.1 (0.7–1.8)           | 1.1 (1.0–2.0)               | 0.376 |
| 3 hours  | 36.0 (28.3–42.5)        | 35.5 (32.1–44.9)            | 0.557 |
| 24 hours | 23.1 (16.8–27.0)        | 21.6 (16.2–29.6)            | 0.468 |
| 48 hours | 21.0 (14.7–25.0)        | 18.6 (13.2–26.6)            | 0.239 |
| hs-TnI (ng/l) |                      |                             |     |
| Preop    | 0.0 (0.0–0.0)           | 0.0 (0.0–0.0)               | 0.836 |
| 3 hours  | 9.4 (4.6–14.5)          | 6.4 (5.1–8.6)               | 0.139 |
| 24 hours | 8.8 (3.9–22.8)          | 9.6 (7.8–11.1)              | 0.093 |
| 48 hours | 7.4 (2.4–21.3)          | 8.1 (6.4–9.8)               | 0.122 |
| NT-pro BNP (pg/ml) |                    |                             |     |
| Preop    | 156.1 (40.9–257.2)      | 82.3 (34.2–324.0)           | 0.449 |
| 3 hours  | 141.4 (62.9–236.0)      | 176.8 (109.1–235.0)         | 0.151 |
| 24 hours | 235.8 (155.9–295.0)     | 221.6 (165.0–358.0)         | 0.246 |
| 48 hours | 285.8 (203.9–347.0)     | 276.6 (217.0–412.0)         | 0.199 |
| PF ratio |                         |                             |     |
| Preop    | 486.8 (447.1–517.1)     | 502.9 (444.2–529.5)         | 0.563 |
| Weaning  | 264.2 (127.5–407.0)     | 297.2 (185.7–375.0)         | 0.299 |
| 3 hours  | 359.3 (267.7–437.5)     | 350.9 (259.8–437.5)         | 0.975 |
| 24 hours | 363.8 (304.0–434.0)     | 357.8 (300.0–417.5)         | 0.884 |
| 48 hours | 513.7 (428.6–646.2)     | 493.7 (416.7–630.0)         | 0.655 |
| Hct (%)  |                         |                             |     |
| Preop    | 38.4 (35.7–41.7)        | 38.7 (37.1–39.5)            | 0.630 |
| Weaning  | 30.5 (29.0–32.0)        | 31.0 (28.0–32.0)            | 0.471 |
| 3 hours  | 32.4 (29.7–34.9)        | 32.3 (30.0–33.1)            | 0.489 |
| 24 hours | 36.5 (34.6–38.3)        | 36.3 (33.1–37.6)            | 0.435 |
| 48 hours | 37.7 (35.8–39.5)        | 37.5 (34.2–38.8)            | 0.391 |
| pH       |                         |                             |     |
| Preop    | 7.4 (7.4–7.5)           | 7.4 (7.4–7.5)               | 0.928 |
| Weaning  | 7.4 ± 0.0               | 7.4 ± 0.0                   | 0.376 |
| 3 hours  | 7.4 (7.4–7.5)           | 7.4 (7.4–7.5)               | 0.406 |
| Continued |                     |                             |     |
revealed that immune status, which could not be determined based on cytokine expression alone, could be examined more precisely based on the expression of CD39 and CD73 in helper T cells, even with confounding factors. The decrease in CD39 and CD73 immediately and 3 hours after weaning from CPB was greater in the sevoflurane group. Similarly, the recovery of CD39 and CD73 after weaning from CPB was weaker in the sevoflurane group. In addition, although not significant, IL-6 was higher immediately after weaning from CPB in the sevoflurane group. Because IL-6 can be induced by IRI related inflammation during CPB, we postulated that sevoflurane has a less marked immune regulatory effect against IRI than propofol. Finally, regarding the changes in CD39, CD73, and IL-6, propofol-based anaesthesia might be more beneficial for minimizing IRI related inflammation during OHS. In addition, IRI related inflammation was closely related to postoperative complications after OHS. Therefore, we anticipate potential benefits from propofol use relative to sevoflurane during OHS by reducing IRI related inflammation and postoperative complications.

The clinical outcomes, including the duration of mechanical ventilation and duration of stays in the intensive care unit (ICU) and hospital, did not differ between the groups in our study. Lurati Buse et al. found that propofol and sevoflurane had similar impacts on myocardial ischemia and postoperative complications. In addition, a recent large scale meta-analysis found no difference in survival between propofol and volatile anaesthetics. However, enhanced expression of CD39 and CD73 in animal models was recently considered as a novel therapeutic approach to avoid inflammatory responses against IRI. Therefore, regulating the expression of CD39 and CD73 by adjusting the propofol dosage could be a helpful approach for minimizing IRI related inflammation and postoperative complications. Because previous studies of the anti-immunosuppressive effects of CD39 and CD73 used animal models, exploring the effects of CD39 and CD73 according to different anaesthetics may be challenging in the clinical setting.

There could be several considerations in the present study. First, adenosine was not measured directly in the present study. However, the half-life of adenosine is extremely short and it is difficult to measure accurately. Instead, recent studies have focused on blocking the adenosine receptor instead of adenosine itself, or on interventions with several endogenous mediators, such as CD39 and CD73, which are responsible for adenosine formation. In this respect, investigating the pattern of CD39 and CD73 expression during OHS may be essential. Second, cytokine production by other leukocyte such as neutrophil and B cells was not measured in the present study. However, the half-life of adenosine is extremely short and it is difficult to measure accurately.

### Methods

#### Study population.

This study was approved by the Institutional Review Board of Konkuk University Medical Centre, Seoul, Korea (IRB #KUH1160064) and carried out in accordance to the relevant guidelines and regulation of the Declaration of Helsinki. This study was registered before patient enrollment at clinicaltrials.gov (NCT02136979, Principal investigator: Seong-Hyop, Kim, Date of registration: May 13, 2014) and was conducted at a single tertiary medical centre (Konkuk University Medical Centre). All patients signed a written informed consent. The study used a prospective randomized design and was conducted according to the original protocol from May 2014 to December 2016 (full protocol available on request).

Patients undergoing OHS were enrolled, and patients were excluded if any of the following criteria were met: 1) age < 20 years, 2) pre-operative infection, 3) pre-operative use of an immunosuppressive agent, and

|                | Propofol group (n = 78) | Sevoflurane group (n = 78) | P     |
|----------------|-------------------------|----------------------------|-------|
| 24 hours       | 7.4 (7.4–7.5)           | 7.4 (7.4–7.5)              | 0.412 |
| 48 hours       | 7.4 (7.4–7.5)           | 7.5 (7.4–7.5)              | 0.310 |

Abbreviations: WBC, white blood cell; Preop, preoperative time; Weaning, immediately after weaning from CPB; CD, C-reactive protein; CK-MB, creatine kinase-MB; hs-TnI, high-sensitivity troponin; NT-pro BNP, N-terminal-pro brain natriuretic peptide; PF ratio, the ratio of arterial oxygen partial pressure to fractional inspired oxygen; Hct, haematocrit.
4) previous history of cancer. Patients were randomly assigned to groups by opening sequentially numbered envelopes containing the randomization assignment (third party allocation). The allocation sequence was generated by the clinical research coordination centre in our hospital, which was not otherwise involved in the trial, with random-permuted block randomization conducted using an interactive internet-based response system. The propofol and sevoflurane groups were anaesthetised by propofol and sevoflurane, respectively. All involved anaesthesiologists, surgeons and attending physicians were blinded to the study. All data were collected by trained observers who also were blinded and did not participate in patient care.

**Anaesthetic regimens.** The anaesthetic technique was standardised between groups. The patient arrived at the operating room without premedication. After establishing routine invasive systemic arterial blood pressure monitoring and non-invasive patient monitoring (pulse oximetry, electrocardiography, cerebral oximetry, and bispectral index [BIS]), anaesthesia was induced using etomidate 0.2 mg/kg. After confirming loss of consciousness, rocuronium (1.0 mg/kg) was administered. For the propofol group, an initial target concentration at the effect-site of propofol, of 1 μg/ml, was administered using a target-controlled infusion device (Orchestra® Base Primea; Fresenius Vial, Brezins, France). For the sevoflurane group, an initial end-expiratory concentration of sevoflurane 1.5 vol% was administered using a vapouriser (Aladin™; Datex-Ohmeda Division Instrumentarium, Bromma, Sweden). The target concentration of propofol and the end-expiratory concentration of sevoflurane

|                      | Propofol group (n=78) | Sevoflurane group (n=78) | P     |
|----------------------|-----------------------|--------------------------|-------|
| IL-1 (%)             |                       |                          |       |
| Preop                | 1.0 (0.5–1.4)         | 1.1 (0.6–1.2)            | 0.687 |
| Weaning              | 1.6 (0.8–1.9)         | 1.6 (0.9–2.4)            | 0.257 |
| 3 hours              | 0.9 (0.5–1.6)         | 0.9 (0.5–1.5)            | 0.622 |
| 24 hours             | 0.6 (0.4–1.0)         | 0.5 (0.3–1.0)            | 0.759 |
| 48 hours             | 0.5 (0.2–0.9)         | 0.4 (0.2–0.9)            | 0.973 |
| IL-6 (%)             |                       |                          |       |
| Preop                | 1.7 (0.7–1.9)         | 1.7 (0.9–2.0)            | 0.535 |
| Weaning              | 1.9 (1.3–2.0)         | 2.4 (1.5–2.6)            | 0.050 |
| 3 hours              | 2.2 (0.9–3.7)         | 1.8 (1.2–3.8)            | 0.894 |
| 24 hours             | 2.1 (1.0–2.8)         | 1.6 (0.5–4.0)            | 0.296 |
| 48 hours             | 2.1 (0.9–2.7)         | 1.5 (0.5–4.0)            | 0.318 |
| IL-10 (%)            |                       |                          |       |
| Preop                | 2.1 (0.7–3.4)         | 2.3 (1.4–4.4)            | 0.825 |
| Weaning              | 1.3 (0.6–2.7)         | 1.3 (0.8–2.4)            | 0.880 |
| 3 hours              | 1.0 (0.4–2.7)         | 1.2 (0.8–1.7)            | 0.287 |
| 24 hours             | 2.7 (1.4–3.8)         | 3.3 (1.1–4.0)            | 0.511 |
| 48 hours             | 2.6 (1.3–3.6)         | 3.2 (0.9–3.9)            | 0.539 |
| IL-17 (%)            |                       |                          |       |
| Preop                | 1.3 (0.5–2.3)         | 1.4 (0.3–2.4)            | 0.444 |
| Weaning              | 3.7 (2.8–5.1)         | 3.7 (2.9–4.6)            | 0.353 |
| 3 hours              | 2.1 (1.2–3.1)         | 2.4 (1.7–3.1)            | 0.073 |
| 24 hours             | 1.9 (0.8–2.1)         | 1.4 (0.2–2.2)            | 0.080 |
| 48 hours             | 1.8 (0.8–2.1)         | 1.3 (0.1–2.2)            | 0.134 |
| IFN-γ (%)            |                       |                          |       |
| Preop                | 4.1 (0.8–7.6)         | 6.7 (3.7–8.3)            | 0.199 |
| Weaning              | 12.9 (1.0–20.1)       | 12.9 (6.7–14.6)          | 0.928 |
| 3 hours              | 12.6 (1.0–19.9)       | 13.9 (10.4–15.4)         | 0.376 |
| 24 hours             | 21.1 (13.1–27.6)      | 17.1 (9.5–23.4)          | 0.136 |
| 48 hours             | 22.8 (14.9–29.1)      | 18.6 (11.1–25.2)         | 0.130 |
| TNF-α (%)            |                       |                          |       |
| Preop                | 3.3 (1.7–4.1)         | 3.1 (2.4–3.8)            | 0.982 |
| Weaning              | 2.5 (0.3–5.1)         | 2.9 (0.5–4.8)            | 0.272 |
| 3 hours              | 3.4 (2.4–4.0)         | 3.0 (1.2–3.9)            | 0.153 |
| 24 hours             | 1.5 (0.9–2.0)         | 1.2 (0.6–3.2)            | 0.357 |
| 48 hours             | 1.3 (0.8–1.8)         | 1.1 (0.5–3.1)            | 0.396 |

Table 4. Changes in cytokine levels during open heart surgery. Data are expressed as median values (25–75%) or means ± standard deviation. The cytokine level was the percentage of each cytokine among total CD4+ T cells. Abbreviations: IL, interleukin; Preop, pre operative time; Weaning, immediate after weaning from cardiopulmonary bypass (CPB); 3 hours, 3 hours after weaning from CPB; 24 hours, 24 hours after weaning from CPB; 48 hours, 48 hours after weaning from CPB; IFN, interferon; TNF, tumour necrosis factor.
were titrated at 0.1 μg/ml and 0.1 vol%, respectively, to maintain BIS values between 40 and 50. In both groups, remifentanil was gradually administered using a target-controlled infusion device. A target concentration of 10 ng/ml was achieved after 10 min of administration of remifentanil and maintained throughout the procedure. Following induction of anaesthesia, patients were ventilated with 40% oxygen in air. The tidal volume was 6 ml/kg of lean body mass and the respiratory rate was adjusted to maintain the partial pressure of end-tidal carbon dioxide between 35 and 40 mmHg. Additional rocuronium was administered under the guidance of peripheral monitoring of neuromuscular transmission. A pulmonary artery catheter was inserted, and transoesophageal echocardiography was done, after anaesthesia induction.

**Management of haemodynamic changes.** Haemodynamic stability was maintained using adequate inotropic and vasoactive agents to ensure that the cardiac index and systemic mean blood pressure were above 2.01/min/m and 60 mmHg, respectively. Fluid administration was performed to meet fluid requirements and replace surgically lost blood until the laboratory values met transfusion indications. Perioperative transfusion was performed according to our institutional protocol. After the end of the surgery, the propofol or sevoflurane was stopped and the patient was transferred to the ICU. For the sedation during the transfer, remifentanil 10 ng/ml was maintained and infused continuously for 60 minutes after arrival at the ICU. Decision-making regarding medical treatment was performed in the ICU by the physicians in charge of the unit, who were blinded to the study, based on institutional protocols.

**Blood samples.** In all patients, blood was sampled to analyse CD39, CD73, and cytokine expression in circulating CD4+ T cells and CD4+CD25+Foxp3+ T cells. Blood samples were obtained before anaesthesia induction and immediately, and 3, 24, and 48 hours after weaning from cardiopulmonary bypass (CPB). Samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes.

**Flow cytometric analysis.** Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples using density-gradient centrifugation over a Ficoll-Hypaque gradient (GE Healthcare, Piscataway, NJ, USA). The PBMCs were washed with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 M KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and resuspended in Roswell Park Memorial Institute (RPMI) medium 1640 with 1% penicillin (BD Biosciences, San Jose, CA, USA) and analysed using FlowJo™ software (Tree Star Inc., Ashland, OR, USA).

**Flow cytometric analysis of CD39 and CD73 expression in CD4+ T cells.** To determine the expression of CD39 and CD73 in circulating CD4+ T cells, isolated PBMCs were stained with peridinin chlorophyll protein complex (PerCP)-conjugated anti-human CD4 (BD Biosciences), fluorescein isothiocyanate (FITC)-conjugated anti-human CD39 (BD Biosciences), and phycoerythrin (PE)-cy7-conjugated anti-human CD73 (BD Biosciences). After washing with fluorescence-activated cell sorting (FACS) buffer (0.1% bovine serum albumin [BSA] in PBS), PBMCs were stained for 30 minutes.

**Flow cytometric analysis of CD39 and CD73 expression in CD4+CD25+Foxp3+ T cells.** The expression of CD39 and CD73 in circulating CD4+CD25+Foxp3+ T cells, were measured using the Human Regulatory T cell Staining Kit (eBioscience, San Diego, CA, USA), according to the manufacturer’s protocol. Single-cell suspensions were incubated with PerCP-conjugated anti-human CD4 (BD Biosciences), allophycocyanin (APC)-conjugated anti-human CD25 (BD Biosciences), FITC-conjugated anti-human CD39 (BD Biosciences), and PE-cy7-conjugated anti-human CD73 (BD Biosciences) antibodies for 30 min in the dark at 4 °C to stain surface-expressed factors. After washing with flow cytometry staining buffer, the PBMCs were incubated with 1 ml freshly prepared FixCyto™ (BD Biosciences) for 10 min at 4 °C. Then, the cells were washed twice with 2 ml freshly prepared FixCyto™ permeabilization buffer. Next, the cells were stained with a PE-conjugated anti-human Foxp3 (eBioscience) antibody for 30 min in the dark at 4 °C. After washing twice, the number of Foxp3-positive cells in the CD4+CD25+ cell gating was evaluated by flow cytometry, and the frequency of Foxp3+ Treg cells was expressed as a percentage of the total CD4+CD25+ cells.

**Flow cytometric analysis of cytokine expression in CD4+ T cells.** To analyse the cytokine production in T cells, PBMCs were isolated from heparinized venous blood using density-gradient centrifugation over a Ficoll-Hypaque gradient (GE Healthcare). The PBMCs were washed with PBS and resuspended in RPMI 1640 medium with 100 U/mL penicillin, 100 U/mL streptomycin and 10% (v/v) heat-inactivated fetal calf serum (HyClone, Logan, UT, USA). After washing, the cells were stained with PerCP-labeled anti-human CD4 (BD Biosciences) at room temperature for 30 min. After washing with FACS buffer (0.1% [v/v] BSA/PBS), the cells were stimulated with 50 ng/ml phorbol myristate acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA) and 1 μg/mL ionomycin (Sigma-Aldrich) in the presence of BD GolgiStop™ (BD Biosciences) for 4 h at 37 °C. The stimulated cells were washed with FACS buffer, fixed for 10 min with 4% (v/v) paraformaldehyde, permeabilized with FACS™ Perm2 (BD Biosciences) according to the manufacturer’s instructions, and stained with FITC-conjugated anti-human IFN-γ, IL-1, IL-6 (BD Biosciences), PE-conjugated anti-human IL-10, IL-17, IFN-γ, and TNF-α (eBioscience) antibodies.

**Measurements.** The following clinical data were obtained: (1) Patient demographic characteristics, including intraoperative drug dosages, fluids, and transfusion requirements; (2) changes in intraoperative haemodynamics; (3) inflammation-related laboratory tests, including white blood cell, neutrophil and lymphocyte counts, erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP); (4) levels of cardiac enzymes, including CK-MB, high-sensitivity troponin (Tn) I, and N-terminal-pro brain natriuretic peptide (NT-pro BNP);
and (5) arterial blood gas analysis, including the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PF ratio), and haematocrit level, potential of hydrogen (pH), and lactate level.

**Statistical analysis.** The primary outcome was the difference in expression of CD39 and CD73 in circulating CD4+ T cells between the propofol and sevoflurane groups. The data for the sample size calculation were drawn from 10 patients per group in our pilot study using G^power (ver. 3.1.9.2, Universität Kiel, Kiel, Germany). The calculated sample size for the primary outcome was 52 in each group for CD39 and 78 in each group for CD73 from the data of our pilot study with an α of 0.05 and power of 0.8. Therefore, we included 78 patients in each group; a total of 173 patients were enrolled in our study considering a dropout rate of 10%.

An independent two-tailed t test was used to compare mean values in cases of continuous normally distributed data. When the data were not distributed normally, the Mann-Whitney U test was used. Intragroup changes and intergroup differences in expression levels were analysed by two way analysis of variance for repeated measurements or the Friedman test, as appropriate. If a significant difference was noted, Student’s t-test or the Mann-Whitney rank-sum test was used to compare group differences with Bonferroni’s correction applied. The chi-square test was used to compare categorical variables, and numbers of patients (n) and proportions (%) were calculated. All calculations were performed using SPSS software (ver. 20.0; IBM SPSS Inc., Chicago, IL, USA). A value of P < 0.05 was taken to indicate statistical significance.

**References**

1. Levy, J. H. & Tanaka, K. A. Inflammatory response to cardiopulmonary bypass. The Annals of thoracic surgery 75, S715–S720, https://doi.org/10.1067/mats.2002.139771 (2003).
2. De Hert, S. & Moerman, A. Myocardial injury and protection related to cardiopulmonary bypass. Best Pract Res Clin Anaesthesiol 29, 137–149, https://doi.org/10.1016/j.bpa.2015.03.002 (2015).
3. Wan, J. P. & et al. Beating heart revascularization with or without cardiopulmonary bypass: evaluation of inflammatory response in a prospective randomized study. The Journal of thoracic and cardiovascular surgery 127, 1624–1631, https://doi.org/10.1016/j.jtcvs.2003.10.043 (2004).
4. Marik, P. E. Propofol: an immunomodulating agent. Pharmacotherapy 25, 28–33s (2005).
5. An, K. et al. Effects of propofol on pulmonary inflammatory response and dysfunction induced by cardiopulmonary bypass. Anesthesiology 106, https://doi.org/10.1097/01.anes.0000253092.47741.cb (2007).
6. Lin, E. & Symons, J. A. Volatile anaesthetic myocardial protection: a review of the current literature. HSR Proc Intensive Care Cardiovasc Anesth 2 (2010).
7. Li, F. & Yuan, Y. Meta-analysis of the cardioprotective effect of sevoflurane versus propofol during cardiac surgery. Propofol and survival: a meta-analysis of randomized clinical trials. Acta anaesthesiologica Scandinavica 59, 17–24, https://doi.org/10.1111/aas.12415 (2015).
8. Antoniolli, L., Pacher, P., Vizi, E. S. & Hasko, G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 19, 355–367, https://doi.org/10.1016/j.molmed.2013.03.005 (2013).
9. Antoniolli, L. et al. Adenosine and inflammation: what’s new on the horizon? Drug Discov Today, https://doi.org/10.1016/j.drudis.2014.02.010 (2014).
10. Eckle, T. et al. Cardioprotection by ecto-S′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115, 1581–1590 (2007).
11. Kohler, D. et al. CD39/CD73 triphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116, 1784–1794, https://doi.org/10.1161/CIRCULATIONAHA.106.669697 (2007).
12. Roberts, V., Lu, B., Rajakumar, S., Cowan, P. J. & Dwyer, K. M. The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury. Puerperal Sinalg 9, 135–143, https://doi.org/10.1007/s11802-013-9432-3 (2013).
13. Sung, S. S. I. et al. Proximal tubule CD73 is critical in renal ischemia-reperfusion injury protection. J. Am. Soc. Nephrol. 28, 889–902, https://doi.org/10.1681/ASN.2016020229 (2017).
14. Kim, M. et al. The volatile anesthetic isoflurane induces ecto-S′-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury. Kidney int 84, 90–103, https://doi.org/10.1038/ki.2013.43 (2013).
15. Bonner, E., Borg, N., Burghoff, S. & Schrader, J. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One 7, e34720, https://doi.org/10.1371/journal.pone.0034720 (2012).
16. Blume, C. et al. Autoimmunity in CD73/ecto-S′-nucleotidase deficient mice induces renal injury. PLoS One 7, e37100, https://doi.org/10.1371/journal.pone.0037100 (2012).
17. Kinsey, G. R. et al. Autocoid adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 23, 1528–1537, https://doi.org/10.1681/ASN.2012010070 (2012).
18. Yang, X.-L., Wang, D., Zhang, G.-Y. & Guo, X.-L. Comparison of the myocaprotective effect of sevoflurane versus propofol in patients undergoing heart valve replacement surgery with cardiopulmonary bypass. BMC Anesthesiology 17, 37, https://doi.org/10.1186/s12871-017-0326-2 (2017).
19. Likhvantsev, V. V. et al. Sevoflurane versus total intravenous anesthesia for isolated coronary artery bypass surgery with cardiopulmonary bypass: a randomized trial. Journal of cardiothoracic and vascular anesthesia 30, https://doi.org/10.1053/j.jvca.2016.02.030 (2016).
20. Bignami, E. et al. Role of cardiac biomarkers (troponin I and CK-MB) as predictors of quality of life and long-term outcome after cardiac surgery. Ann Card Anaesth 12, 22–26 (2009).
21. Bette, D. A. et al. Role of sevoflurane in organ protection during cardiac surgery in children: a randomized controlled trial. Interact Cardiovasc Thorac Surg 20, https://doi.org/10.1093/icvts/ivv381 (2015).
22. Desborough, J. The stress response to trauma and surgery. British journal of anaesthesia 85, 109–117 (2000).
23. Cardinale, E. et al. Perioperative period: immunological modifications. Int J Immunopathol Pharmacol 24, S3–12 (2011).
24. Iwagaki, H. et al. Blood transfusion and postoperative plasma cytokine antagonist levels in colorectal cancer patients. Hepato-gastroenterology 48, 1351–1354 (2001).
25. Lu and et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation 126, 801–804, https://doi.org/10.1161/circulationaha.112.120414 (2012).
26. Covarrubias, R. et al. Role of the CD39/CD73 Purinergic Pathway in Modulating Articular Thrombosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 36, 1809, https://doi.org/10.1161/ATVBAHA.116.307374 (2016).
27. Bon, M. R., Fernandez, D., Flores-Santibanez, F., Rosenblatt, M. & Sauma, D. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression. FEBS Lett 29, 00652–00653, https://doi.org/10.1016/j.febslet.2015.07.027 (2015).
28. Wheeler, D. G. et al. Transgenic swine: expression of human CD39 protects against myocardial injury. Journal of molecular and cellular cardiology 52, 958–961, https://doi.org/10.1016/j.yycard.2012.01.002 (2012).
29. Crikis, S. et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 10, 2586–2595, https://doi.org/10.1111/j.1600-6143.2010.03257.x (2010).

Acknowledgements
This article was based on the research for thesis for degree of doctor by C.-S. O. This paper was written as part of Konkuk University’s research support program for its faculty on sabbatical leave in 2017. This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (NRF-2016R1A5A2012284).

Author Contributions
S.-H.K. contributed to the study design, helped write and initial draft and revised it accordingly. C.-S.O. contributed to data analysis and interpretation, and manuscript writing. K.K., W.-S.K. and J.-S.K. helped data collection. N.-S.W., P.-S.K. and S.-H.L. helped data interpretation. All authors reviewed and approved submission of the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28505-8.

Competing Interests:
The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018